Northpond Ventures — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
EnPlusOne Biosciencesenplusonebio.comin𝕏Aug 2022
En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications.
BiotechDeep TechWatertown, US
Daniel Ahlstedt(Executive Officer, Director)Jonathan Rittichier(Founder)in
BoardAndrew Lee(Director)inSteven Kasok(Director)
Board seatPaxton Major· per SEC Form D
Co-investorsBreakout VenturesCoatue Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.